Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease
2 other identifiers
interventional
160
1 country
1
Brief Summary
We propose to study the intestinal secretion of ASCA by evaluating them in biopsy culture supernatants from a cohort of patients suffering from CD (n=80) and a cohort of control patients (UC (n=40) and patients without IBD (n=40 )).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2008
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2008
CompletedFirst Submitted
Initial submission to the registry
October 8, 2008
CompletedFirst Posted
Study publicly available on registry
October 9, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2010
CompletedMay 7, 2026
August 1, 2014
1.9 years
October 8, 2008
May 4, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Compare the performances of the dosage of the ASCA in floating it of culture of intestinal biopsies in that of their dosage in the serum
24 months
Secondary Outcomes (1)
Determine if the patients reached by disease of crohn not presenting ASCA in their serum represent one under group of disease of crohn
24 months
Study Arms (3)
1
OTHERPatients with crohn disease
2
OTHERPatients reached by hemorrhagic first side-colitis
3
OTHERPatients controls
Interventions
Eligibility Criteria
You may qualify if:
- Patients reached by disease of crohn
- patients reached by hemorrhagic first side-colitis
You may not qualify if:
- Forms ileales or ano-périneales pure of disease of crohn
- indefinite colitis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Laboratoire d'Immunologie - Hopital de la Conception
Marseille, 13005, France
Related Publications (1)
Bertin D, Grimaud JC, Lesavre N, Benelmouloud C, Desjeux A, Garcia S, Desplat-Jego S. Targeting tissular immune response improves diagnostic performance of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease. PLoS One. 2013 Nov 26;8(11):e80433. doi: 10.1371/journal.pone.0080433. eCollection 2013.
PMID: 24303014RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sophie Desplat-Jego, MD
Assistance Publique des Hopitaux de Marseille
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 8, 2008
First Posted
October 9, 2008
Study Start
June 1, 2008
Primary Completion
May 1, 2010
Study Completion
August 1, 2010
Last Updated
May 7, 2026
Record last verified: 2014-08